SCHEMBL6325694

SCHEMBL6325694

COc1ccc(S(=O)(=O)N(C)[C@H](C)CO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
POLB P06746 1/20 0.57
KMT2A Q03164 1/20 0.57
MMP1 P03956 6/20 0.48
MMP13 P45452 6/20 0.48
MMP8 P22894 4/20 0.48
MMP7 P09237 3/20 0.48
MMP12 P39900 3/20 0.48
KEAP1 Q14145 4/20 0.48
NFE2L2 Q16236 2/20 0.48
ALDH1A1 P00352 2/20 0.46
USP2 O75604 1/20 0.46
PKM P14618 1/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325691 1.00 MEN1 (0.57) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6330960 0.85 CA12 (0.49) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6330962 0.85 CA12 (0.49) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6323221 0.84 MEN1 (0.61) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6323218 0.84 MEN1 (0.61) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6324814 0.84 LMNA (0.60) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6324817 0.84 LMNA (0.60) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6323456 0.82 CA12 (0.51) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6323458 0.82 CA12 (0.51) MEN1POLBKMT2AMMP1MMP13
SCHEMBL6321475 0.82 ESR1 (0.49) MEN1POLBKMT2AALDH1A1PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MEN1 2943/4885POLB 2981/4885KMT2A 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.